Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity

Journal of Immunology

Volumn 177, Issue 4, 2006, Pages 2324-2330

  Taneichi, Maiko ^a   Ishida, Hideaki ^b   Kajino, Kiichi ^b   Ogasawara, Kazumasa ^b   Tanaka, Yuriko ^a   Kasai, Michiyuki ^a   Mori, Masahito ^c   Nishida, Mitsuhiro ^c   Yamamura, Hiroyuki ^c   Mizuguchi, Junichiro ^d   Uchida, Tetsuya ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c JAPAN ENERGY CORPORATION   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 10; OVALBUMIN; OVALBUMIN[257-264]; PEPTIDE DERIVATIVE; SATURATED FATTY ACID; TUMOR VACCINE; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DEGRADATION; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LIPID COMPOSITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; TUMOR IMMUNITY;

EID: 33746903553     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.4.2324     Document Type: Article

References (44)

1. + T cell adoptive immunotherapy. Immunity 13: 265-276.
2. Shankaran, V., H. Ikeda, A. T. Bruce, J. M., White, P. E. Swanson, J. J. Old, and R. D. Schreiber. 2001. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
3. Zhan, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, S. C. Rubin, and G. Coukos. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348: 203-213.
4. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
5. Sznol, M., and D. R. Parkinson. 1993. Clinical applications of IL-2. Oncology 8: 61-67.
6. Hu, J., W. Kindsvogel, S. Busby, M. C. Bailey, Y. Shi, and P. D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177: 1681-1690.
7. Blattman, J. N., and P. D. Greenherg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
8. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
9. Mark, A., B. Bjorksten, and M. Granstrom. 1995. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminum-adsorbed and fluid DT-vaccines. Vaccine 13: 669-673.
10. Aggerbeck, H., J. Wantzin, and I. Heon. 1996. Booster vaccination against diphtheria and tetanus in man: comparison of three different vaccine formulations-III. Vaccine 14: 1265-1272.
11. Nothdurft, H. D., T. Jelinek, A. Marschang, H. Maiwald, A. Kapaun, and T. Loscher. 1996. Adverse reactions to Japanese encephalitis vaccine in travelers. J. Infect. 32: 119-122.
12. Gregoriadis, G. 1990. Immunological adjuvants: a role for liposomes. Immunol. Today 11: 89-97.
13. Wassef, N. M., C. R. Alving, and R. L. Richards. 1994. Liposomes as carriers for vaccines. Immunomethods 4: 217-222.
14. Alving, C. R., V. Koulchin, G. M. Glenn, and M. Rao. 1995. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145: 5-31.
15. Green, S., J. D. Fortier, J. Madsen, G. Swartz, L. Einck, E. Gubish, and C. Nancy. 1995. Liposomal vaccines. In Immunology of Proteins and Peptides VIII. M. Z. Atassi and G. S. Bixler., eds. Plenum, New York, pp. 83-92.
16. De Haan, A., J. F. C. Tomee, J. P. Huchshorn, and J. Wilschut. 1995. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13: 1320-1324.
17. Gluck, R. 1995. Liposomal presentation of antigens for human vaccines. Pharm. Biotechnol. 6: 325-345.
18. Perrie, Y., P. M. Frederik, and G. Gregoriadis. 2001. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19: 3301-3310.
19. Naito, S., A. Horino, M. Nakayama, Y. Nakano, T. Nagai, M. Mizuguchi, K. Komuro, and T. Uchida. 1996. Ovalbumin-liposome conjugate induces IgG but not IgE antibody production. Int. Arch. Allergy Immunol. 109: 223-228.
20. Nakano, Y., M. Mori, S. Nishinohara, Y. Takita, S. Naito, A. Horino, H. Kato, M. Taneichi, K. Komuro, and T. Uchida. 1999. Antigen-specific, IgE-selective unresponsiveness induced by antigen-liposome conjugates: comparison of four different conjugation methods for the coupling of antigen to liposome. Int. Arch. Allergy Immunol. 120: 199-208.
21. Naito, S., M. Taneichi, H. Kato, Y. Ami, Y. Suzaki, M. Mori, Y. Nakano, H. Yamamura, K. Morokuma, K. Ohkuma, et al. 2002. Selective inhibition of systemic anti-OVA IgE production in response to oral preadministration with OVA-liposome conjugates. Int. Arch. Allergy Immunol. 129: 314-319.
22. Yoshikawa, T., T. Uchida, S. Naito, K. Komuro, J. Chiba, T. Kurata, and S. Tamura. 2000. Suppression of IgE antibody response to ovalbumin by intranasal administration of liposome-conjugated ovalbumin. Int. Arch. Allergy Immunol. 121: 108-115.
23. Nakano, Y., M. Mori, S. Nishinohara, Y. Takita, S. Naito, H. Kato, M. Taneichi, K. Komuro, and T. Uchida. 2001. Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjug. Chem. 12: 391-395.
24. Chang, E. Y., Y. Zheng, D. Holowka, and B. Baird. 1995. Alteration of lipid composition modulates FCεRI signaling in RBL-2H3 cells. Biochemistry 34: 4376-4384.
25. Phillips, N. C., L. Gagne, N. Ivanoff, and G. Riveau. 1996. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 14: 898-904.
26. Hincha, D. K., A. E. Oliver, and J. H. Crowe. 1999. Lipid composition determines the effect of arbutin on the stability of membranes. Biophys. J. 77: 2024-2034.
27. Moody, D. B., V. Briken, T. Y. Cheng, C. Roura-Mir, M. R. Guy, D. H. Geho, M. L. Tykocinski, G. S. Besra, and S. A. Porcelli. 2002. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat. Immunol. 3: 435-442.
28. Uchida, T., S. T. Ju, A. Fay, Y. N. Liu, and M. E. Dorf. 1985. Functional analysis of macrophage hyhridomas: I. Production and initial characterization. J. Immunol. 134: 772-778.
29. Hermel, E., J. Yuan, and J. J. Monaco. 1995. Characterization of polymorphism within the H2-M MHC class II loci. Immunogenetics 42: 136-142.
30. Ishida, H., R. Hastings, J. Kearney, and M. Howard. 1992. Continuous anti-interleukin-10 antibody administration depletes mice of LY-1 B cells but not conventional B cells. J. Exp. Med. 175: 1213-1220.
31. Rock, K. L. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17: 131-137.
32. Carbone, F. R., and M. J. Bevan. 1990. Class I-restricted processing and presentation of exogeneous cell-associated antigen in vivo. J. Exp. Med. 171: 377-387.
33. Liu, T., X. Zhou, C. Orvell, E. Leferer, H. G. Ljunggren, and M. Jondal. 1995. Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J. Immunol. 154: 3147-3155.
34. Zinkernagel, R. M. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 232: 2385-2392.
35. Houde, M., S. Berholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M. F. Princlotta, P. Thibault, D. Sacks, and M. Desjardins. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 402-406.
36. Ackerman, A. L., and P. Cresswell. 2004. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol. 5: 678-684.
37. Dermine, S., D. E. Gilham, D. M. Shaw, E. J. Davidson, E. K. Meziane, A. Armstrong, R. E. Hawkins, and P. Stern. 2004. Vaccine and antibody-directed T cell tumor immunotherapy. Biochem. Biophys. Acta 1704: 11-35.
38. Vicari, A. P., C. Chiodoni, C. Vaure, S. Ait-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, M. P. Colombo, et al. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196: 541-549.
39. Gregoriadis, G. 1994. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods 4: 210-216.
40. Suzaki, Y., Y. Ami, N. Nagata, S. Naito, H. Kato, M. Taneichi, M. Takahashi, T. Komiya, S. Satoh, F. Gondaira, et al. 2002. Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates. Int. Arch. Allergy Immunol. 127: 294-298.
41. Taneichi, M., S. Naito, H. Kato, K. Koinuro, and T. Uchida. 2002. T cell-independent regulation of IgE antibody production induced by surface-linked liposomal antigen. J. Immunol. 169: 4246-4252.
42. Garcon, N., G. Gregoriadis, M. Taylor, and J. Summerfield. 1988. Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology 64: 743-745.
43. Tanaka, Y., M. Kasai, M. Taneichi, S. Naito, H. Kato, M. Mori, M. Nishida, N. Maekawa, H. Yamamura, K. Komuro, and T. Uchida. 2004. Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages. Bioconjug. Chem. 15: 35-40.
44. Forni, G., P. L. Lollini, P. Musiani, and M. P. Colombo. 2000. Immunoprevention of cancer: is the time ripe? Cancer Res. 60: 2571-2575.